Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial
Tóm tắt
To identify disease characteristics leading to progression of joint damage in patients with early rheumatoid arthritis (RA) treated with methotrexate (MTX) versus those treated with infliximab plus MTX.
Patients who had not previously been treated with MTX with active RA were randomly assigned to receive escalating doses of MTX up to 20 mg/week plus placebo or infliximab at weeks 0, 2, and 6, and every 8 weeks thereafter through week 46. Radiographic joint damage was assessed using the modified Sharp/van der Heijde score (SHS). The relationship between disease activity measures at baseline and week 14, as well as those averaged over time, were examined in relation to the change in SHS from baseline through week 54.
C‐reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), and swollen joint count were associated with greater joint damage progression in the MTX‐only group, while none of these parameters was associated with progression in the infliximab plus MTX group. Mean changes in SHS among patients in the highest CRP (≥3 mg/dl) and ESR (≥52 mm/hour) tertiles in the MTX‐only group were 5.62 and 5.89, respectively, compared with 0.73 and 1.12 in the infliximab plus MTX group (
High CRP level, high ESR, or persistent disease activity was associated with greater radiographic progression in the group taking MTX alone, while little radiographic progression was seen in patients receiving both MTX and infliximab, regardless of the abnormal levels of these traditional predictors.
Từ khóa
Tài liệu tham khảo
Van Leeuwen MA, 1994, Interrelationship of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiologic damage, physical disability, joint counts, and acute phase reactants, J Rheumatol, 21, 425
Graudal N, 2000, Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: long term course and association to radiographic progression, J Rheumatol, 27, 47
Guillemin F, 2003, Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients, J Rheumatol, 30, 2585
Smolen JS, 2003, A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures, Clin Exp Rheumatol, 21, S209
Aletaha D, 2002, Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis: an observational study, J Rheumatol, 29, 1631
KoepkeJ BullB van AssendelftO.Reference procedure for the erythrocyte sedimentation rate (ESR) test.National Committee for Clinical Laboratory Standards;1988. Document H2–A2.
Stites DP, 1997, Medical immunology, 211
Fisher LD, 1993, Biostatistics: a methodology for the health sciences
Kalden JR, 2002, Expanding role of biologic agents in rheumatoid arthritis, J Rheumatol Suppl, 66, 27